Although IBM had partnered with various medical institutions for decades previously, primarily through the use of punched cards to gather statistical data, its work on the polio vaccine marked the company’s entry into the field of epidemiology. Today, with polio lingering in some parts of the world, IBM researchers are continuing to harness access to massive computational power and using their expertise in mathematical modeling to support biologists at the University of California, San Francisco; Stanford University; and the University of Haifa, as they strive to engineer a new type of antiviral agent for viruses such as polio. Additionally, the company contributes to multiple projects and partnerships aimed at improving disease prevention and patient care.
One such effort led to the Spatiotemporal Epidemiological Modeler (STEM), an open-source tool that can help forecast the potential spread of infectious diseases such dengue fever, the H5N1 virus and others. Another produced the Public Health Information Affinity Domain (PHIAD), a scalable network that enables clinics and labs to electronically share clinical surveillance data with public health officials to help provide real-time detection of infectious disease outbreaks.
In parallel, IBM used STEM and PHIAD in partnership with Mexico’s Ministry of Health to develop new models on H1N1 when swine flu cases in Mexico City reached pandemic proportions in 2009–2010. In 2016, the company joined the fight against the Zika virus, donating highly localized data from The Weather Company, an IBM business, to the US Fund for UNICEF. And in early 2020, in collaboration with the White House Office of Science and Technology Policy, the US Department of Energy and many others, IBM helped to launch the COVID-19 High Performance Computing Consortium. The effort is slated to produce an unprecedented amount of computing power — 16 systems with more than 330 petaflops, 775,000 CPU cores, 34,000 GPUs and counting — to help researchers everywhere better understand COVID-19, its treatments and potential cures.
With data-driven epidemiology a norm in the 21st century, IBM’s efforts to pioneer and advance the field persist, including partnerships with governments, healthcare agencies and industry to crunch vaccine efficacy data, model the relative merits and effectiveness of lockdown strategies, and increase the overall health of the general population.